Molecular Cloning and Characterization of a Subtilisin-Like Protease from Arabidopsis Thaliana
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders. -
J. Gen. Appl. Microbiol. Doi 10.2323/Jgam.2019.04.005 ©2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation
Advance Publication J. Gen. Appl. Microbiol. doi 10.2323/jgam.2019.04.005 ©2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation 1 Genome Sequencing, Purification, and Biochemical Characterization of a 2 Strongly Fibrinolytic Enzyme from Bacillus amyloliquefaciens Jxnuwx-1 isolated 3 from Chinese Traditional Douchi 4 (Received November 29, 2018; Accepted April 22, 2019; J-STAGE Advance publication date: August 14, 2019) * 5 Huilin Yang, Lin Yang, Xiang Li, Hao Li, Zongcai Tu, Xiaolan Wang 6 Key Lab of Protection and Utilization of Subtropic Plant Resources of Jiangxi 7 Province, Jiangxi Normal University 99 Ziyang Road, Nanchang 330022, China * 8 Corresponding author: Xiaolan Wang, PhD, Key Lab of Protection and Utilization 9 of Subtropic Plant Resources of Jiangxi Province, Jiangxi Normal University 99 10 Ziyang Road, Nanchang 330022, China. Tel: 0086-791-88210391. 11 Email: [email protected]. 12 Short title: B. amyloliquefaciens fibrinolytic enzyme 13 14 * Key Lab of Protection and Utilization of Subtropic Plant Resources of Jiangxi Province, Jiangxi Normal University 99 Ziyang Road, Nanchang 330022, China. Email:[email protected] (X.Wang) 1 15 Abbreviation 16 CVDs: Cardiovascular diseases; u-PA: urokinase-type plasminogen activator; t-PA: 17 tissue plasminogen activator; PMSF: phenylmethanesulfonyl fluoride; SBTI: soybean 18 trypsin inhibitor; EDTA: ethylenediaminetetraacetic acid; TLCK: N-Tosyl-L-Lysine 19 chloromethyl ketone; TPCK: N-α-Tosyl-L-phenylalanine chloromethyl ketone; pNA: 20 p-nitroaniline; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel 21 electrophoresis; GO: Gene Ontology 2 22 23 Summary 24 A strongly fibrinolytic enzyme was purified from Bacillus amyloliquefaciens 25 Jxnuwx-1, found in Chinese traditional fermented black soya bean (douchi). -
B1–Proteases As Molecular Targets of Drug Development
Abstracts B1–Proteases as Molecular Targets of Drug Development B1-001 lin release from the beta cells. Furthermore, GLP-1 also stimu- DPP-IV structure and inhibitor design lates beta cell growth and insulin biosynthesis, inhibits glucagon H. B. Rasmussen1, S. Branner1, N. Wagtmann3, J. R. Bjelke1 and secretion, reduces free fatty acids and delays gastric emptying. A. B. Kanstrup2 GLP-1 has therefore been suggested as a potentially new treat- 1Protein Engineering, Novo Nordisk A/S, Bagsvaerd, Denmark, ment for type 2 diabetes. However, GLP-1 is very rapidly degra- 2Medicinal Chemistry, Novo Nordisk A/S, Maaloev, Denmark, ded in the bloodstream by the enzyme dipeptidyl peptidase IV 3Discovery Biology, Novo Nordisk A/S, Maaloev, DENMARK. (DPP-IV; EC 3.4.14.5). A very promising approach to harvest E-mail: [email protected] the beneficial effect of GLP-1 in the treatment of diabetes is to inhibit the DPP-IV enzyme, thereby enhancing the levels of The incretin hormones GLP-1 and GIP are released from the gut endogenously intact circulating GLP-1. The three dimensional during meals, and serve as enhancers of glucose stimulated insu- structure of human DPP-IV in complex with various inhibitors 138 Abstracts creates a better understanding of the specificity and selectivity of drug-like transition-state inhibitors but can be utilized for the this enzyme and allows for further exploration and design of new design of non-transition-state inhibitors that compete for sub- therapeutic inhibitors. The majority of the currently known DPP- strate binding. Besides carrying out proteolytic activity, the IV inhibitors consist of an alpha amino acid pyrrolidine core, to ectodomain of memapsin 2 also interacts with APP leading to which substituents have been added to optimize affinity, potency, the endocytosis of both proteins into the endosomes where APP enzyme selectivity, oral bioavailability, and duration of action. -
Subtilase Variants
(19) & (11) EP 2 333 055 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 15.06.2011 Bulletin 2011/24 C12N 9/54 (2006.01) C11D 3/386 (2006.01) C12N 1/15 (2006.01) C12N 1/19 (2006.01) (2006.01) (21) Application number: 10180093.6 C12N 1/21 (22) Date of filing: 12.10.2001 (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • Nørregaard-Madsen, Mads MC NL PT SE TR DK-3560, Birkerød (DK) • Larsen, Line, Bloch (30) Priority: 13.10.2000 DK 200001528 DK-2880, Bagsværd (DK) • Hansen, Peter Kamp (62) Document number(s) of the earlier application(s) in DK-4320, Lejre (DK) accordance with Art. 76 EPC: 01978206.9 / 1 326 966 Remarks: This application was filed on 27-09-2010 as a (71) Applicant: Novozymes A/S divisional application to the application mentioned 2880 Bagsvaerd (DK) under INID code 62. (54) Subtilase variants (57) Novel subtilase variants having a reduced ten- dry detergent compositions and dishwash composition, dency towards inhibition by substances present in eggs, including automatic dishwash compositions. Also, isolat- such as trypsin inhibitor type IV- 0. In particular, variants ed DNA sequences encoding the variants, expression comprising at least one additional amino acid residue vectors, host cells, and methods for producing and using between positions 42-43, 51-56, 155-161, 187-190, the variants of the invention. Further, cleaning and de- 216-217, 217-218 or 218-219 (in BASBPN numbering). tergent compositions comprising the variants are dis- These subtilase variants are useful exhibiting excellent closed. -
Secretion and Autoproteolytic Maturation of Subtilisin (Protein Transport/Proteolytic Processing/Mutagenesis) SCOTT D
Proc. Nati. Acad. Sci. USA Vol. 83, pp. 3096-3100, May 1986 Biochemistry Secretion and autoproteolytic maturation of subtilisin (protein transport/proteolytic processing/mutagenesis) SCOTT D. POWER*, ROBIN M. ADAMS*, AND JAMES A. WELLSt *Department of Protein Chemistry, Genencor, Inc., 180 Kimball Way, South San Francisco, CA 94080; and tDepartment of Biocatalysis, Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 Communicated by M. J. Osborn, December 19, 1985 ABSTRACT The sequence of the cloned Bacillus MATERIALS AND METHODS amyloliquefaciens subtilisin gene suggested that this secreted serine protease is produced as a larger precursor, designated T4 lysozyme was provided by Ron Wetzel (Genentech). T4 preprosubtilisin [Wells, J. A., Ferrari, E., Henner, D. J., DNA kinase was from Bethesda Research Laboratories. Estell, D. A. & Chen, E. Y. (1983) Nucleic Acids Res. 11, BamHI, EcoRI, and T4 ligase were from New England 7911-7925]. Biochemical evidence presented here shows that a Biolabs. DNA polymerase large fragment (Klenow fragment) subtilisin precursor is produced in Bacillus subtilis hosts. The was obtained from Boehringer Mannheim. Enzymes were precursor is first localized in the cell membrane, reaching a used as recommended by their respective suppliers. Eugenio steady-state level of -1000 sites per cell. Mutations in the Ferrari and Dennis Henner kindly provided the following B. subtilisin gene that alter a catalytically critical residue (i.e., subtilis strains used in these studies (6, 14): BG2036 (Apr-, aspartate +32 -* asparagine), or delete the carboxyl-terminal Npr-), BG2019 (Apr-, Npr+), BG2044 (Apr', Npr-), and portion of the enzyme that contains catalytically critical resi- I-168 (Apr', Npr+). -
Fibronectin-Binding Protein B (Fnbpb)
ARTICLE cro Fibronectin-binding protein B (FnBPB) from Staphylococcus aureus protects against the antimicrobial activity of histones Received for publication, September 5, 2018, and in revised form, December 17, 2018 Published, Papers in Press, January 8, 2019, DOI 10.1074/jbc.RA118.005707 X Giampiero Pietrocola‡1, Giulia Nobile‡, Mariangela J. Alfeo‡, Timothy J. Foster§, Joan A. Geoghegan¶, Vincenzo De Filippisʈ, and X Pietro Speziale‡**2 From the ‡Department of Molecular Medicine, Unit of Biochemistry, University of Pavia, 27100 Pavia, Italy, the §Microbiology Department, Trinity College Dublin, Dublin 2, Ireland, the ¶Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College, Dublin, Dublin 2, Ireland, the ʈLaboratory of Protein Chemistry and Molecular Hematology, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 36131 Padova, Italy, and the **Department of Industrial and Information Engineering, University of Pavia, 27100 Pavia, Italy Edited by Roger J. Colbran Staphylococcus aureus is a Gram-positive bacterium that can tizing pneumoniae (1, 2). Strains that are resistant to multiple Downloaded from cause both superficial and deep-seated infections. Histones antibiotics are a major problem in healthcare settings in devel- released by neutrophils kill bacteria by binding to the bacterial oped countries (3). These are referred to as hospital-associated cell surface and causing membrane damage. We postulated that methicillin-resistant S. aureus (MRSA)3 and occur in individu- cell wall–anchored proteins protect S. aureus from the bacteri- als with pre-disposing risk factors, such as surgical wounds and cidal effects of histones by binding to and sequestering histones indwelling medical devices (4, 5). -
Purification and Characterization of a Subtilisin D5, a Fibrinolytic Enzyme of Bacillus Amyloliquefaciens DJ-5 Isolated from Doenjang
Food Sci. Biotechnol. Vol. 18, No. 2, pp. 500 ~ 505 (2009) ⓒ The Korean Society of Food Science and Technology Purification and Characterization of a Subtilisin D5, a Fibrinolytic Enzyme of Bacillus amyloliquefaciens DJ-5 Isolated from Doenjang Nack-Shick Choi, Dong-Min Chung1, Yun-Jon Han, Seung-Ho Kim1, and Jae Jun Song* Enzyme Based Fusion Technology Research Team, Jeonbuk Branch Institute, Korea Research Iinstitute Bioscience & Biotechnology (KRIBB), Jeongeup, Jeonbuk 580-185, Korea 1Systemic Proteomics Research Center, Korea Research Iinstitute Bioscience & Biotechnology (KRIBB), Daejeon 305-333, Korea Abstract The fibrinolytic enzyme, subtilisin D5, was purified from the culture supernatant of the isolated Bacillus amyloliquefaciens DJ-5. The molecular weight of subtilisin D5 was estimated to be 30 kDa. Subtilisin D5 was optimally active at pH 10.0 and 45oC. Subtilisin D5 had high degrading activity for the Aα-chain of human fibrinogen and hydrolyzed the Bβ-chain slowly, but did not affect the γ-chain, indicating that it is an α-fibrinogenase. Subtilisin D5 was completely inhibited by phenylmethylsulfonyl fluoride, indicating that it belongs to the serine protease. The specific activity (F/C, fibrinolytic/caseinolytic activity) of subtilisin D5 was 2.37 and 3.52 times higher than those of subtilisin BPN’ and Carlsberg, respectively. Subtilisin D5 exhibited high specificity for Meo-Suc-Arg-Pro-Tyr-pNA (S-2586), a synthetic chromogenic substrate for chymotrypsin. The first 15 amino acid residues of the N-terminal sequence of subtilisin D5 are AQSVPYGISQIKAPA; this sequence is identical to that of subtilisin NAT and subtilisin E. Keywords: Bacillus amyloliquefaciens, doenjang, fibrinolytic enzyme, subtilisin D5 Introduction blood for more than 3 hr. -
Purification and Characterization of a Thrombolytic Enzyme Produced by a New Strain of Bacillus Subtilis
J. Microbiol. Biotechnol. 2021. 31(2): 327–337 https://doi.org/10.4014/jmb.2008.08010 Review Purification and Characterization of a Thrombolytic Enzyme Produced by a New Strain of Bacillus subtilis Jorge Frias1*, Duarte Toubarro1, Alexandra Fraga5, Claudia Botelho2,3,4, José Teixeira2, Jorge Pedrosa5, and Nelson Simões1 1CBA – Biotechnology Centre of Azores, Faculty of Sciences and Technology, University of Azores, 9500-321 Ponta Delgada, Açores. Portugal 2CEB - Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal 3CBMA – Centre of Molecular and Environmental Biology, University of Minho, 4710-057 Braga, Portugal 4INL - International Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal 5ICVS - Life and Health Research Institute, University of Minho, 4710-057 Braga, Portugal Fibrinolytic enzymes with a direct mechanism of action and safer properties are currently requested for thrombolytic therapy. This paper reports on a new enzyme capable of degrading blood clots directly without impairing blood coagulation. This enzyme is also non-cytotoxic and constitutes an alternative to other thrombolytic enzymes known to cause undesired side effects. Twenty-four Bacillus isolates were screened for production of fibrinolytic enzymes using a fibrin agar plate. Based on produced activity, isolate S127e was selected and identified as B. subtilis using the 16S rDNA gene sequence. This strain is of biotechnological interest for producing high fibrinolytic yield and consequently has potential in the industrial field. The purified fibrinolytic enzyme has a molecular mass of 27.3 kDa, a predicted pI of 6.6, and a maximal affinity for Ala-Ala-Pro-Phe. This enzyme was almost completely inhibited by chymostatin with optimal activity at 48oC and pH 7. -
Characterisation of the Major Extracellular Proteases of Stenotrophomonas Maltophilia and Their Effects on Pulmonary Antiproteases
pathogens Article Characterisation of the Major Extracellular Proteases of Stenotrophomonas maltophilia and Their Effects on Pulmonary Antiproteases Kevin Molloy 1, Stephen G. Smith 2, Gerard Cagney 3, Eugene T. Dillon 3, Catherine M. Greene 4,* and Noel G. McElvaney 1 1 Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, D02 YN77 Dublin, Ireland 2 Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland 3 School of Biomolecular and Biomedical Science, University College Dublin, D04 V1W8 Dublin, Ireland 4 Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Beaumont Hospital, D02 YN77 Dublin, Ireland * Correspondence: [email protected] Received: 31 May 2019; Accepted: 22 June 2019; Published: 28 June 2019 Abstract: Stenotrophomonas maltophilia is an emerging global opportunistic pathogen that has been appearing with increasing prevalence in cystic fibrosis (CF). A secreted protease from S. maltophilia has been reported as its chief potential virulence factor. Here, using the reference clinical strain S. maltophilia K279a, the major secreted proteases were identified. Protein biochemistry and mass spectrometry were carried out on K279a culture supernatant. The effect of K279a culture supernatant on cleavage and anti-neutrophil elastase activity of the three majors pulmonary antiproteases was quantified. A deletion mutant of S. maltophilia lacking expression of a protease was constructed. The serine proteases StmPR1, StmPR2 and StmPR3, in addition to chitinase A and an outer membrane esterase were identified in culture supernatants. Protease activity was incompletely abrogated in a K279a-DStmPR1: Erm mutant. Wild type K279a culture supernatant degraded alpha-1 antitrypsin (AAT), secretory leucoprotease inhibitor (SLPI) and elafin, important components of the lung’s innate immune defences. -
The Utilization of Alpha-1 Anti-Trypsin (A1AT) in Infectious Disease Monitoring and Treatment Irene L
JMID/ 2019; 9 (1):51-58 Journal of Microbiology and Infectious Diseases doi: 10.5799/jmid.537178 REVIEW ARTICLE The Utilization of Alpha-1 Anti-trypsin (A1AT) in Infectious Disease Monitoring and Treatment Irene L. Indalao, Agustiningsih Agustiningsih, Eka Pratiwi, Kartika Dewi Puspa, Hartanti Dian Ikawati, Ririn Ramadhany Center for Research and Development of Biomedical and Basic Technology of Health, National Institute of Health Research and Development, Ministry of Health Republic of Indonesia ABSTRACT Alpha one anti-trypsin (A1AT) is a major serine protease inhibitor found circulating in human blood. A1AT related studies mainly focus on A1AT potential biomarker as well as therapeutic target in non-infectious diseases. Their findings indicate A1AT beneficial features may also be applied for monitoring and treating infectious disease. However, only a few studies have reviewed A1AT’s useful properties as a biomarker and therapeutic agent for infectious diseases. This narrative review aims to summarize growing evidences that support the idea of utilizing A1AT as a tool for monitoring and therapy for infectious diseases. A1AT showed potential as a biomarker for a wide spectrum of infectious disease, from virus, bacteria, to parasite. Its level and functionality were proposed to predict risk for disease susceptibility or progression and to indicate response therapy. As promising therapeutic agent in various infectious diseases, the administration of A1AT has shown antimicrobial activity, immunomodulatory and anti-apoptotic effect, in addition to more familiar function, suppressing excessive proteolysis. The broad utilization of A1AT, both as biomarker and therapeutic agent, in studies on infectious diseases seems promising. However, there are issues need to be investigated further before establishing its feasibility as a monitoring and therapy tool against infection diseases. -
University of California Riverside
UNIVERSITY OF CALIFORNIA RIVERSIDE Mechanisms of Selenomethionine and Hypersaline Developmental Toxicity in Japanese Medaka (Oryzias latipes) A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Environmental Toxicology by Allison Justine Kupsco August 2016 Dissertation Committee: Dr. Daniel Schlenk, Chairperson Dr. Morris Maduro Dr. Nicole zur Nieden Copyright by Allison Justine Kupsco 2016 The Dissertation of Allison Justine Kupsco is approved: Committee Chairperson University of California, Riverside Acknowledgements This dissertation would not have been possible without the support of many people. First, my advisor, Dr. Dan Schlenk, was invaluable in not only his guidance and resources for this project, but also in providing me with the opportunities to grow and develop as a scientist. Without the time and effort he put into guiding me, this would not have been possible. In addition to advice about this dissertation, he also provided me with numerous networking and presentation opportunities through attendance of many conferences. I would also like to thank my committee members, Dr. Nicole zur Nieden and Dr. Morris Maduro for their support and advice. There have been many past and present labmates that have also aided in the dissertation through training, advice and emotional support. Dr. Aileen Maldonado, Dr. Lindley Maryoung, and Dr. Jordan Crago all participated in training me in lab techniques. Rafid Sikder was always eager to help and assisted in fish care and in data collected in Chapter 2. Luisa Becker Bertotto, Scott Coffin, Marissa Giroux and Sara Vliet provided important emotional support and entertainment during long lab hours. And especially, I want to thank Graciel Diamante for her invaluable advice, commiseration and emotional support throughout our 4 years working together. -
An Arabidopsis Mutant Over-Expressing Subtilase SBT4.13 Uncovers the Role of Oxidative Stress in the Inhibition of Growth by Intracellular Acidification
International Journal of Molecular Sciences Article An Arabidopsis Mutant Over-Expressing Subtilase SBT4.13 Uncovers the Role of Oxidative Stress in the Inhibition of Growth by Intracellular Acidification Gaetano Bissoli 1 , Jesús Muñoz-Bertomeu 2 , Eduardo Bueso 1, Enric Sayas 1, Edgardo A. Vilcara 1, Amelia Felipo 1, Regina Niñoles 1 , Lourdes Rubio 3 , José A. Fernández 3 and Ramón Serrano 1,* 1 Instituto de Biología Molecular y Celular de Plantas, Universidad Politécnica de Valencia-Consejo Superior de Investigaciones Científicas, Camino de Vera, 46022 Valencia, Spain 2 Departament de Biologia Vegetal, Facultat de Farmàcia, Universitat de València, 46100 València, Spain 3 Departamento de Botánica y Fisiología Vegetal, Universidad de Málaga, 29071 Málaga, Spain * Correspondence: [email protected] Received: 30 January 2020; Accepted: 8 February 2020; Published: 10 February 2020 Abstract: Intracellular acid stress inhibits plant growth by unknown mechanisms and it occurs in acidic soils and as consequence of other stresses. In order to identify mechanisms of acid toxicity, we screened activation-tagging lines of Arabidopsis thaliana for tolerance to intracellular acidification induced by organic acids. A dominant mutant, sbt4.13-1D, was isolated twice and shown to over-express subtilase SBT4.13, a protease secreted into endoplasmic reticulum. Activity measurements and immuno-detection indicate that the mutant contains less plasma membrane H+-ATPase (PMA) than wild type, explaining the small size, electrical depolarization and decreased cytosolic pH of the mutant but not organic acid tolerance. Addition of acetic acid to wild-type plantlets induces production of ROS (Reactive Oxygen Species) measured by dichlorodihydrofluorescein diacetate. Acid-induced ROS production is greatly decreased in sbt4.13-1D and atrboh-D,F mutants.